Edwards v. Basel Pharmaceuticals

United States Court of Appeals for the Tenth Circuit · Torts

116 F.3d 1341 (1997)

Updated July 19, 2026

Tortsfailure to warnprescription drugslearned intermediary rulewrongful deathnicotine patchpatient insertprescribing physician

Facts

Plaintiff brought a wrongful death action after her husband died of a heart attack while smoking cigarettes and wearing two of Basel's Habitrol nicotine patches. Basel had provided the prescribing physician with materials specifically noting the fatal risk of nicotine overdose, but the patient package insert stated only that an overdose might cause fainting and did not mention fatal reactions. Basel represented that both the patient insert and the physician information were mandated and approved by the FDA, and it argued that its compliance with that mandate barred liability based on inadequate patient warnings. Plaintiff argued that FDA-mandated patient warnings triggered an exception to Oklahoma's learned intermediary rule.

Issue

Whether, after Basel admitted that the FDA mandated direct patient warnings and that it complied with that mandate, the court's prior certification and remand were improper because the exact source and content of the FDA mandate had not been established. More broadly, the question was whether an FDA mandate for direct patient warnings undercuts the learned intermediary rule so that Basel may still owe a common-law duty to provide adequate consumer warnings.

Rule

When the FDA requires that warnings be given directly to the patient with a prescribed drug, the learned intermediary rule does not automatically shield the manufacturer from liability merely because the prescribing physician was adequately warned. Compliance with FDA minimum warning requirements does not necessarily satisfy the manufacturer's duty to warn the consumer; the warnings must be nonmisleading and adequate under state common law. For purposes of this case, the existence of an FDA mandate for direct patient warnings, once admitted and uncontroverted, is sufficient to trigger that duty analysis without further qualification as to the mandate's regulatory source, content, or form.

🔒

See the holding & full analysis

Create a free KwikCourt account to unlock the rest of this brief — and practice the case.

The court's holding and reasoning
Doctrine tests, pitfalls & exam hypotheticals
10 practice questions + 4 AI-graded essays on this case

Free sample · practice this case

Test yourself

One of 10 multiple-choice questions for this case. Pick an answer to see why.

In Tulsa, Orion Therapeutics makes a prescription migraine spray. Orion gave neurologists a detailed warning about the risk of stroke, and it also included an FDA-required leaflet for patients that mentioned only dizziness and nausea. After a patient suffers a stroke, Orion argues that adequate warning to the prescribing physician alone bars any claim based on the leaflet.

Under the governing rule, what is the strongest response to Orion's argument?

Explanation. When the FDA requires direct patient warnings for a prescription drug, the learned intermediary rule does not automatically shield the manufacturer merely because the prescribing physician was adequately warned. The patient's warning must still be assessed for adequacy under state common law, and FDA compliance alone is not necessarily enough.